Malaria chemoprevention and drug resistance: a review of the literature and policy implications
CV Plowe - Malaria Journal, 2022 - Springer
Chemoprevention strategies reduce malaria disease and death, but the efficacy of anti-
malarial drugs used for chemoprevention is perennially threatened by drug resistance. This …
malarial drugs used for chemoprevention is perennially threatened by drug resistance. This …
Poor birth outcomes in malaria in pregnancy: recent insights into mechanisms and prevention approaches
Pregnant women in malaria-endemic regions are susceptible to malaria in pregnancy, which
has adverse consequences on birth outcomes, including having small for gestational age …
has adverse consequences on birth outcomes, including having small for gestational age …
Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda
Abstract Background In Uganda, artemether-lumefantrine is recommended for malaria
treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug …
treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug …
Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on …
Background Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–
piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria …
piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria …
[HTML][HTML] Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer
B Bai, F Wu, K Ying, Y Xu, L Shan, Y Lv, X Gao, D Xu… - Theranostics, 2021 - ncbi.nlm.nih.gov
Colitis-associated colorectal cancer (CAC) develops from chronic intestinal inflammation.
Dihydroartemisinin (DHA) is an antimalarial drug exhibiting anti-inflammatory and anti-tumor …
Dihydroartemisinin (DHA) is an antimalarial drug exhibiting anti-inflammatory and anti-tumor …
Chloroquine and sulfadoxine–pyrimethamine resistance in Sub-Saharan Africa—A review
Malaria is a great concern for global health and accounts for a large amount of morbidity and
mortality, particularly in Africa, with sub-Saharan Africa carrying the greatest burden of the …
mortality, particularly in Africa, with sub-Saharan Africa carrying the greatest burden of the …
Global trend of Plasmodium malariae and Plasmodium ovale spp. malaria infections in the last two decades (2000–2020): a systematic review and meta-analysis
J Hawadak, RR Dongang Nana, V Singh - Parasites & vectors, 2021 - Springer
Background Recent studies indicate that the prevalence of non-falciparum malaria,
including Plasmodium malariae and Plasmodium ovale spp., is increasing, with some …
including Plasmodium malariae and Plasmodium ovale spp., is increasing, with some …
Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs
M Saito, V Briand, AM Min… - The lancet child & …, 2020 - thelancet.com
All malaria infections are harmful to both the pregnant mother and the developing fetus. One
in ten maternal deaths in malaria endemic countries are estimated to result from …
in ten maternal deaths in malaria endemic countries are estimated to result from …
Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation …
ME Roh, FO Ter Kuile, F Rerolle… - The Lancet Global …, 2020 - thelancet.com
Background Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women
that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine …
that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine …
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa
Abstract Realizing Effectiveness Across Continents with Hydroxyurea (REACH,
NCT01966731) provides hydroxyurea at maximum tolerated dose (MTD) for children with …
NCT01966731) provides hydroxyurea at maximum tolerated dose (MTD) for children with …